Merck Sharp + Dohme Corp.

Michael A Plotkin

Paul E Finke

Jianming Bao

Srikanth Venkatraman

F Anthony Romero

Feroze Ujjainwalla

Jason M Cox

Harold B Wood

John S Debenham

Mariappan Chelliah

Clare London

Weiguo Liu

Unmesh G Shah

Joseph Leslie Duffy

Christopher Joseph Sinz

Feng Ye

Ping Lan

Edward C Sherer

Debra L Ondeyka

Sriram Tyagarajan

Yi Zang

Henry M Vaccaro

Zahid Hussain

Remond Moningka

Zhongxiang Sun

Hong Dong Chu

Revathi Reddy Katipally

Keith A Eagen

Patrick Shao

Aaron Zwicker

Joseph L Duffy

Keith Eagen

Unmesh Shah

Skikanth Venkatraman

Zahid Hussian

Anthony Romero

The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing diabetes, hyperlipidemia, obesity, inflammation related disorders, and related diseases and conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR120. Pharmaceutical compositions and methods of treatment are also included. 

Substituted spiropiperidinyl compounds useful as GPR120 agonists

Substituted spirocyclic amines of structural formula (I) are selective antagonists of the somatostatin subtype receptor 5 (SSTR5) and are useful for the treatment, control or prevention of disorders responsive to antagonism of SSTR5, such as Type 2 diabetes, insulin resistance, lipid disorders, obesity, atherosclerosis, Metabolic Syndrome, depression, and anxiety. 

Spiroxazolidinone compounds

Growing community of inventors

Frenchtown, NJ, United States of America

Michael A Plotkin